Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p. — Clinical Trial Site

52 Registered trials

15 Currently recruiting

Organisation

Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p.

Location

Elblag, Poland

Identifier

ORG-100043495

Address

Ul. Studzienna 35-36/a, 82-300, Poland

Departments

-
#40038: nap
#401: Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka Partnerska
#7816: Rheumatology
40038: Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka Partnerska
408_reumatology
Centrum Kliniczno - Badawcze
Centrum Kliniczno - Badawcze J. Brzezicki, B. Górnikiewicz-Brzezicka Lekarze Spółka Partnerska
Centrum Kliniczno - Badawcze J.Brzezicki, B.Górnikiewicz-Brzezicka Lekarze Spółka Partnerska
Centrum Kliniczno – Badawcze J. Brzezicki, B. Górnikiewicz-Brzezicka Lekarze Spółka Partnerska
Centrum Kliniczno – Badawcze J. Brzezicki,B. Górnikiewicz-Brzezicka Lekarze Spółka Partnerska
Centrum Kliniczno- Badawcze
Centrum Kliniczno-Badawcze
Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze spolka partnerska
Dermatology
Dermatology Department
N/A
NA
Nie dotyczy
PL10001: Rheumatology
Rheumatology

Clinical trials at this site (52)

Search interface

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Pending

2025-523579-47-00 moderate to severe rheumatoid arthritis (RA) 4
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting

2025-522782-30-00 CCI 3 2026-04-07
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or… Recruiting

2025-521034-28-00 Moderate to Severe Rheumatoid Arthritis (RA) 4 2025-12-05
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting

2025-520721-21-00 Rheumatoid Arthritis 4 2025-10-20
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting

2025-523141-10-00 Active Psoriatic Arthritis 4 2026-03-20
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Hypertriglyceridemia (HTG) 5 2025-12-08
A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis Recruiting

2024-519291-11-00 Psoriatic Arthritis 4 2025-07-25
A Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior… Recruiting

2024-513112-99-00 Active Psoriatic Arthritis Stratified by Prior Biologic 5 2025-06-13
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting

2024-517284-23-00 Active Psoriatic Arthritis 5 2025-04-23
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended

2025-521791-63-00 Moderately to Severely Active Rheumatologic Disease 4 2025-12-18
A Phase 2b to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With ACPA-Positive Rheumatoid Arthritis Ended

2024-515973-82-00 ACPA-Positive Rheumatoid Arthritis 4 2025-06-23
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18